Get the Stockscreener App
65.60
0.03%
-0.02
After Hours:
65.60
Cytokinetics Inc stock is traded at $65.60, with a volume of 2.65M.
It is down -0.03% in the last 24 hours and down -8.80% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$65.62
Open:
$66.45
24h Volume:
2.65M
Relative Volume:
1.39
Market Cap:
$9.12B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-9.5866
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
+1.45%
1M Performance:
-8.80%
6M Performance:
-1.69%
1Y Performance:
+16.48%
1-Day Range:
$64.49
$66.91
1-Week Range:
$64.25
$67.27
52-Week Range:
$54.30
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
65.60 | 8.99B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
CYTK4910847 Bond Profile: Coupon and Redemption - TradingView
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - uk.finance.yahoo.com
Cytokinetics (CYTK) Launches ASPEN-HCM Study to Evaluate Myqorzo in Obstructive Hypertrophic Cardiomyopathy - GuruFocus
Cytokinetics launches real-world study of heart drug MYQORZO - Investing.com
Cytokinetics Announces Start of ASPEN-HCM Real-World Study of MYQORZO in Symptomatic Obstructive HCM - Quiver Quantitative
Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy - TradingView
Equity in earnings of Cytokinetics, Incorporated – HAN:KK3A - TradingView
Form 4 Cytokinetics Inc For: 29 September By Investing.com - Investing.com Nigeria
Cytokinetics CEO Robert Blum sells $490,949 in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $490,950, According to a Recent SEC Filing - marketscreener.com
At $65.46 a share, Cytokinetics (CYTK) CEO Robert Blum sold 7,500 shares after exercising options. - Stock Titan
Weekly Recap: MYQORZO US/Germany uptake and COMET/AMBER program updates - TradingView
Cytokinetics (CYTK) Insider Trading Activity 2026 $CYTK - MarketBeat
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference - Yahoo Finance
CYTK5615147 Bond Profile: Coupon and Redemption - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance Singapore
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics at bernstein healthcare forum: push beyond first launch By Investing.com - Investing.com South Africa
Cytokinetics at bernstein healthcare forum: push beyond first launch - Investing.com
Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story? - Yahoo Finance
Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus
Form 4 Cytokinetics Inc For: 22 September - Investing.com India
Form 4 Cytokinetics Inc For: 22 September By Investing.com - Investing.com Canada
Cytokinetics EVP Fady Malik sells $239k in company stock - Investing.com
Cytokinetics EVP Fady Malik sells $239k in company stock By Investing.com - Investing.com Nigeria
Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Benzinga
Cytokinetics stock steadies after recent data and guidance updates - AD HOC NEWS
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Cytokinetics CEO, President & Director Robert Blum Sells 44% Of Holding - simplywall.st
Cytokinetics CEO Blum’s trust sells $6.7m in company shares By Investing.com - za.investing.com
Cytokinetics director Robert Landry sells $72,130 in shares - Investing.com
Cytokinetics CEO Blum’s trust sells $6.7m in company shares - Investing.com
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Trust tied to Cytokinetics (NASDAQ: CYTK) CEO moves to sell shares - Stock Titan
Family trust tied to Cytokinetics (NASDAQ: CYTK) CEO just sold about 98,000 shares - stocktitan.net
Cytokinetics at Morgan Stanley conference: launch gains and broader bets - Investing.com
Patient advocacy groups have until Oct. 2 to apply for heart disease outreach grants - Stock Titan
Cytokinetics, Incorporated rStock Price, RCYTK Price, Live Charts, and Marketcap - Coinbase
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO |
Sep 28 '26 |
Sale |
65.46 |
7,500 |
490,950 |
278,544 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Sale |
68.29 |
3,500 |
239,015 |
153,902 |
0.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):